-
1
-
-
84962877705
-
Zika virus: History, emergence, biology, and prospects for control
-
Weaver, S. C., F. Costa, M. A. Garcia-Blanco, A. I. Ko, G. S. Ribeiro, G. Saade, P. Y. Shi, and N. Vasilakis. 2016. Zika virus: history, emergence, biology, and prospects for control. Antiviral Res. 130: 69-80.
-
(2016)
Antiviral Res.
, vol.130
, pp. 69-80
-
-
Weaver, S.C.1
Costa, F.2
Garcia-Blanco, M.A.3
Ko, A.I.4
Ribeiro, G.S.5
Saade, G.6
Shi, P.Y.7
Vasilakis, N.8
-
2
-
-
84985987120
-
Zika virus: Implications for public health
-
Focosi, D., F. Maggi, and M. Pistello. 2016. Zika virus: implications for public health. Clin. Infect. Dis. 63: 227-233.
-
(2016)
Clin. Infect. Dis.
, vol.63
, pp. 227-233
-
-
Focosi, D.1
Maggi, F.2
Pistello, M.3
-
3
-
-
84964276686
-
Zika virus and birth defects-reviewing the evidence for causality
-
Rasmussen, S. A., D. J. Jamieson, M. A. Honein, and L. R. Petersen. 2016. Zika virus and birth defects-reviewing the evidence for causality. N. Engl. J. Med. 374: 1981-1987.
-
(2016)
N. Engl. J. Med.
, vol.374
, pp. 1981-1987
-
-
Rasmussen, S.A.1
Jamieson, D.J.2
Honein, M.A.3
Petersen, L.R.4
-
4
-
-
84921735883
-
Potential sexual transmission of Zika virus
-
Musso, D., C. Roche, E. Robin, T. Nhan, A. Teissier, and V. M. Cao-Lormeau. 2015. Potential sexual transmission of Zika virus. Emerg. Infect. Dis. 21: 359-361.
-
(2015)
Emerg. Infect. Dis.
, vol.21
, pp. 359-361
-
-
Musso, D.1
Roche, C.2
Robin, E.3
Nhan, T.4
Teissier, A.5
Cao-Lormeau, V.M.6
-
5
-
-
84994059378
-
Zika virus: Immunity and vaccine development
-
Pierson, T. C., and B. S. Graham. 2016. Zika virus: immunity and vaccine development. Cell 167: 625-631.
-
(2016)
Cell
, vol.167
, pp. 625-631
-
-
Pierson, T.C.1
Graham, B.S.2
-
6
-
-
84971641047
-
Scoping review of the Zika virus literature
-
Waddell, L. A., and J. D. Greig. 2016. Scoping review of the Zika virus literature. PLoS One 11: e0156376.
-
(2016)
PLoS One
, vol.11
, pp. e0156376
-
-
Waddell, L.A.1
Greig, J.D.2
-
7
-
-
0038013205
-
The antibody response to smallpox vaccination as measured by a tissue culture plaque method
-
Cutchins, E., J. Warren, and W. P. Jones. 1960. The antibody response to smallpox vaccination as measured by a tissue culture plaque method. J. Immunol. 85: 275-283.
-
(1960)
J. Immunol.
, vol.85
, pp. 275-283
-
-
Cutchins, E.1
Warren, J.2
Jones, W.P.3
-
8
-
-
80054989227
-
Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent
-
Heiber, J. F., and G. N. Barber. 2011. Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J. Virol. 85: 10440-10450.
-
(2011)
J. Virol.
, vol.85
, pp. 10440-10450
-
-
Heiber, J.F.1
Barber, G.N.2
-
9
-
-
11344285489
-
VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway
-
Faria, P. A., P. Chakraborty, A. Levay, G. N. Barber, H. J. Ezelle, J. Enninga, C. Arana, J. van Deursen, and B. M. Fontoura. 2005. VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. Mol. Cell 17: 93-102.
-
(2005)
Mol. Cell
, vol.17
, pp. 93-102
-
-
Faria, P.A.1
Chakraborty, P.2
Levay, A.3
Barber, G.N.4
Ezelle, H.J.5
Enninga, J.6
Arana, C.7
Van Deursen, J.8
Fontoura, B.M.9
-
10
-
-
0027478991
-
Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein
-
Konishi, E., and P. W. Mason. 1993. Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein. J. Virol. 67: 1672-1675.
-
(1993)
J. Virol.
, vol.67
, pp. 1672-1675
-
-
Konishi, E.1
Mason, P.W.2
-
11
-
-
58249118005
-
Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01
-
Iyer, A. V., B. Pahar, M. J. Boudreaux, N. Wakamatsu, A. F. Roy, V. N. Chouljenko, A. Baghian, C. Apetrei, P. A. Marx, and K. G. Kousoulas. 2009. Recombinant vesicular stomatitis virus-based West Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent West Nile virus strain LSU-AR01. Vaccine 27: 893-903.
-
(2009)
Vaccine
, vol.27
, pp. 893-903
-
-
Iyer, A.V.1
Pahar, B.2
Boudreaux, M.J.3
Wakamatsu, N.4
Roy, A.F.5
Chouljenko, V.N.6
Baghian, A.7
Apetrei, C.8
Marx, P.A.9
Kousoulas, K.G.10
-
12
-
-
0036140461
-
Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease
-
Fernandez, M., M. Porosnicu, D. Markovic, and G. N. Barber. 2002. Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J. Virol. 76: 895-904.
-
(2002)
J. Virol.
, vol.76
, pp. 895-904
-
-
Fernandez, M.1
Porosnicu, M.2
Markovic, D.3
Barber, G.N.4
-
13
-
-
0036315015
-
Adding genes to the RNA genome of vesicular stomatitis virus: Positional effects on stability of expression
-
Wertz, G. W., R. Moudy, and L. A. Ball. 2002. Adding genes to the RNA genome of vesicular stomatitis virus: positional effects on stability of expression. J. Virol. 76: 7642-7650.
-
(2002)
J. Virol.
, vol.76
, pp. 7642-7650
-
-
Wertz, G.W.1
Moudy, R.2
Ball, L.A.3
-
14
-
-
0033646858
-
Vesicular stomatitis virus (VSV) therapy of tumors
-
Balachandran, S., and G. N. Barber. 2000. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 50: 135-138.
-
(2000)
IUBMB Life
, vol.50
, pp. 135-138
-
-
Balachandran, S.1
Barber, G.N.2
-
15
-
-
0042208208
-
Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity
-
Obuchi, M., M. Fernandez, and G. N. Barber. 2003. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity. J. Virol. 77: 8843-8856.
-
(2003)
J. Virol.
, vol.77
, pp. 8843-8856
-
-
Obuchi, M.1
Fernandez, M.2
Barber, G.N.3
|